DOSE OF REALITY: BIG PHARMA PUSHES FOR POLICY TO KEEP DRUG PRICES HIGH IN RECONCILIATION TAX BILL
Jun 5, 2025
Big Pharma is at it again, working overtime to pass a policy that would cost… Read More
© 2025 CSRXP- All Rights Reserved
Blog Posts
DOSE OF REALITY: BIG PHARMA SETS NEW RECORD FOR OUT-OF-CONTROL LAUNCH PRICES
May 23, 2025
Reuters Analysis Finds Prices for Drugs First Entering the Market More Than… Read More
BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON
Apr 16, 2025
Big Pharma Giant Johnson & Johnson Reports Earnings That Beating Wall… Read More
FACT SHEET: BIG PHARMA’S PATENT ABUSE COSTS AMERICAN PATIENTS, TAXPAYERS AND THE U.S. HEALTH CARE SYSTEM BILLIONS OF DOLLARS
Apr 2, 2025
BIG PHARMA’S PATENT ABUSE IS THE ROOT CAUSE OF OUT-OF-CONTROL PRESCRIPTION… Read More
THEY SAID IT! PRESIDENT TRUMP CALLS OUT BIG PHARMA’S EGREGIOUS PRICING FOR DIABETES AND WEIGHT LOSS DRUGS IN U.S. MARKET
Feb 19, 2025
Brand Name Manufacturers’ Prices for Blockbuster GLP-1 Medications Are… Read More
CSRXP STATEMENT ON CONFIRMATION OF RFK JR AS SECRETARY OF U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
Feb 13, 2025
Campaign Looks Forward to Working with Kennedy and the Administration to Lower… Read More
BIG PHARMA EARNINGS WATCH: GILEAD
Feb 13, 2025
Brand Name Drug Company Known for Egregious Product-Hopping Strategy Beats… Read More
BIG PHARMA EARNINGS WATCH: ASTRAZENECA, BRISTOL MYERS SQUIBB AND ELI LILLY
Feb 12, 2025
Eli Lilly Signals Plan to Maintain Unsustainably High Prices on Blockbuster… Read More
BIG PHARMA EARNINGS WATCH: MERCK AND PFIZER
Feb 7, 2025
Pharmaceutical Giants Continue to Outperform Wall Street Projections While… Read More
BIG PHARMA EARNINGS WATCH: AMGEN, GSK AND NOVO NORDISK
Feb 7, 2025
Major Pharmaceutical Companies Continue Growing Revenues While Sticking With… Read More
BIG PHARMA EARNINGS WATCH: ABBVIE, NOVARTIS AND ROCHE
Feb 6, 2025
Big Pharma Giants Report Higher-Than-Expected Q4 Earnings Amid Continued Price… Read More
BIG PHARMA EARNINGS WATCH: JOHNSON & JOHNSON
Jan 30, 2025
Johnson & Johnson Beats Wall Street Analysts’ Expectations Fueled by… Read More